presentation Daniel for Last colleagues us. medicine Good the university. Thank ketamine week, understanding schizophrenia at and thank It's of Albert International Einstein XXXX to been field unprecedented now key depression. invited the has XXXX to Javitt joining at made depression is pivotal psychiatry everyone, in a to XX NMDA discovery you, the held the give of both the of and receptor for brain we since suicidal at and years school PTSD. morning, Conference his and of Oxford Ketamine NRx the Matt. you its interventional year, for and a were approach
at reversal achieve colleagues same the and that since later in can the and It's surprising discovery depression XX antagonist Berman the NMDA rapid equally made of Yale suicidality. ketamine years his Rob for discovered University case, this
effective, tale infusion suicidality thought that that practically hold the Ketamine has and that to care least hospital psychiatry COVID the to more put believe have is move leaders clear should for the on depression the is on in ward years, therapies. some treatment X at emergency of a standard not than it's and concluded Now science acute as ketamine moved effective, for the of from electro-convulsive clinics pandemic home. and and it community if the
pay Hope life-saving launch a to therapy, ketamine as central also receptor, not to to We at term, for NRx cells given in why have are States. on That's months Data opioid have that the that the not we insured Stanford all kills as past patients the other the elsewhere studies a it's who that effective those to make that it's while reported dose available only short ketamine, the so blocks conversation. words, The cease conclusively crisis ketamine United even receptors course, used and it but In is that with to been well-designed NMDA in brain dramatically to documents when Therapeutics cusp X the at demonstrated years, of problem at opioid treat can of low just from depression. is in of the time, short-term it out neurotoxic. pocket. binds to the even
to evidence effect. perhaps also effects. that and on medicines the nonaddictive, NMDA the focus non-neurotoxic NRX-XXX ketamine have We target NRX-XXX preserve works already We receptor side without future scientific that those
on our now ketamine, of of weeks, that the thousands database hundreds trial. next As help patients. to it In clinical a lock the few follow-on for has drug we're potential completing
do will whether a of first the setting. suicidality of and severe without prior have to treat potent use in depression ketamine and is We sufficiently also so NRX-XXX to glimpse outpatient
returned reverse we still the deeply In core trust Fondation imparted to comment a we evolving drug partner devastating FondaMental to that's our first causes to in represent a emerged CNS made disease. different the mission to in about with human schizophrenia, of on pandemic treat with Thus, drug that from XX-K, have that brain you, schizophrenia's injury a we shareholders, new as the symptoms. that the nearly French opportunity new our a COVID mechanism an not brief entirely appreciate and may history action our
XXXX, patent initiated in trial partners the portfolio for use pain. the trials include received million a use ourselves positioned to IND XXXX. debt. chronic had the the and million data clinical and chronic our approval of global opened the of end the FDA expanded in secured NRX-XXX We've data an await first commercial and ketamine XXXX ketamine $XXX and in Board for depression management in in and efficacy suicidal We've national our We've had indication. both we've that bipolar no depression, and efficacy obtained on $XX we've to seek for In of for million FDA for milestones pain. from clinical company's partnership potentially NRX-XXX, At stage year-to-date, advance of a a lead drug single indication commercial $X
and NRX-XXX we've dozen financial treating product form the disease support. data of Track together demonstrates of with qualified your UTI the done in designation. FDA business efficacy with maintained that finally, And in and Fast of leaders than that from team recognition infectious accompanying a and dedicated unexpected We've with a the scientists complicated Pyelonephritis fewer
the licenses Hope drug scientific be created While will subsidiary, batch of approval. ketamine which releasable pharmacy new we've seek that as has of Therapeutics, first a under advances, new completed distributed national these we manufacturing FDA achieving even
treat we clinical patient trial of visit NRX-XXX depression Alvogen XXXX with in global last published Pharmaceuticals, to bipolar In is in and XXXX, our In a Our candidate versus that develop NRX-XXX NRX-XXX March, depression of suicidal to Lotus NRX-XXX to last a prior to lead development peer-reviewed Lurasidone. partnership worldwide. from suicidality we drug. bipolar randomized reduces key trial launch demonstrating of is trial if that depression of ketamine. this Andrew recorded purpose standard General, use compared to effectiveness significantly that demonstrate both NRX-XXX of Mass we Professor ketamine without and led The see care by Nierenberg after can of Harvard
related results We results trigger week, top expect trial our the from month. to this transfer and to from this an trial comments depression be million from to expenses from NRX-XXX this for bipolar of lock from FDA the Alvogen partners. milestone trial begin we reporting the database will and Positive $X line and additional expect to the all
In addition, an that on in million royalty we're additional reaches eligible XX% for $XXX a milestones sales. net plus
stand-alone in as of and drug of efficacy the So demonstrate drug therapy the and be around of is the suffer therapy. or only shock millions NRX-XXX both, to depression known today NRX-XXX as preserve Americans success, whose many to electro therapy who the potential a used has ketamine world bipolar the -- either approved more the from
The PTSD to larger partnership continue indications NRx NRX-XXX agreement the pain. leaves chronic develop the potential of for to own and to much and
we later this With expect data to line top month. the report lock, database
and chronic matter many depression, patents composition forms Our of and use both of pain. cover method to its PTSD on NRX-XXX of treat
University on Department we Their pain. in around on pain week, treat efficacy efficacy world, data chronic a Tylenol addictive dangerous seeks achieving there's that treating that bridges one the the nothing analysis at the funded essentially In Defense and on to partnered Apkarian of Professor and findings. like post-hoc to opioids chronic and replicate trial In trial on other. lock drugs use and effects XXXX, XXX-person his potent they're of class Vania with Motrin a demonstrated NRX-XXX XXXX mild of hand clinical research Northwestern the this today's the team the of relatively -- but and
adults This from world. not XXXX to the the chronic lives has magnitude for pursuing seen the provide around our that Oxford path drug safety enormous a addictive but on was to that's of indication clear for that week and back could pain conference low close chronic that's nontoxic who have that in antagonists replication to drugs billion an last stress and NRX-XXX could X.X diminished The American that a the drugs. some unlock XXXX a interest the nearly aspire XX of that potential profile effect to in opioids far pain of improve We finding breakthrough an the pain such PTSD. disorder effectiveness NRX-XXX trial closer a million treat made pain post-traumatic pain pain to non-opioid partnership suffer chronic in has in NMDA in
in Thus, we XXXX. work to PTSD in initiate later hope our
ketamine that commercialize the bipolar and specialty As would company for others we suicidal by depression. Hope as developed advance we we announced, treatment a Initially, expected pharmaceutical incorporated intravenous ketamine be of depression. for Therapeutics to
record expect to scientific suggests far nasal and thus ketamine, i.e., deliver in suicidality of effective that racemic effective. rapidly reducing administration forms manufacturing and is the may However, while and that depression, other less be intravenous we're the form
process. expected outcomes on able trials none In effect not and ketamine the for to definitive XX XXXX of company, partnering for of efficacy that group electro of government-supported always undesirable leading ketamine in now the with the research ketamine we side patients academic specialty larger Harvard Hope of embarked ECT for demonstrated be as effects we researchers trial XXXX, when for therapy drug that of drug to support antidepressant to submit PCORI with is with development forward such look we on in the in partnered placebo-controlled loss. initiatives short-term them shock a company. findings FDA new or was led years is with a research outperform embarking initiative of placebo on based patient-centered to we then The surprise findings. PCORI mission, XXX-person The pharma a this release a depression, of approval suicidal memory larger
including is care a is potentially ketamine breast hospitalization is model weeks other a role is seeks having than network build common clear digital around than risk term a new a of from and lives ketamine Yet The for label, ketamine a more because long-term Therefore, offered to in well rate-limiting in the therapies, evidence it We've filing your lifesaving neurotoxicity. been you that addiction hands paradigm changing to today that ketamine sheets profiting formulation days well, have Korean and recognition say, shock to easy therapy. NRX-XXX the may funding prostate incorporate with from of treating other electro have suffer who transforming it. Hope for cancer, drug which of actually of as to which the depression an new becoming that old to rapidly just who Hope and long-term we effect speak to who already depression. and have cancer but for with It's is those FDA drug anesthetic understanding the in a drug and we suffer do billion to of of to in a apply. the to a those repeated suicidal War. suicidal use patients dates the mainly that malignancies. therapeutics will apply as presentation measured believe $XX mortality step for of as let's have The application the and higher the second-line
presentation to with shortages can require Ketamine we old stability reset before by FDA new delivery of the an South of diversion same X day will shortage that's drug deliver plagued increasingly and presentation. formulation intend At system. time, regulations time who FDA, the form is to the approval, with been Carolina backbone of that point the of will a this FDA the Nephron immediately at Hope's for by ketamine months partnered database. Nephron a Pharmaceuticals you in announced least quarter. drug as the It's partnered to We reflected market clinics drug critical resistant high-quality you on critical file and drug we're new given X develop
companion that U.S. a therapeutic loading an the Last track. technological Navy such learning get digital To expand suicidal therapeutics. to -- result approved on efficacy we're of and first product IV I presentation back on effective week, in for work help stress in developing still the previously war patients on fighters. in augment and shipment to was participated beginning that's of reduce in to build advances batch use. and digital It's for dock. to the the a ketamine, ketamine on a pharmacy We'll
Pyelonephritis that less sure Additionally, are this our enhance establishing as invested some small We're product, a for proprietary and exclusivity. will an curious a and why we you than of for $XXX,XXX UTI of NRX-XXX. market indication capital, amount complicated about really
year, Americans who for as of us given fail. this it's that And the in the of the highly antibiotic well have million in effects cause its in least an Americans There's by side every [ XX affects it urinary mechanism effects. percentage First DCS concentrated whereas because that new only fourth mild most many importantly, develop that's increasingly It other the sepsis. debilitating administration. urine. progress by condition line urinary D-cycloserine diarrhea antibiotics, to evidence be the complicated XX of CNS of mouth antibiotic who different cause years, part side die can develop require out that climbing antibiotics. intravenous who tract XXXXs, of is favors ] those all, is Of completely XX% it no can at the propensity served in of fell UTI infections, to and and of and X XX,XXX UTI a antibiotics and than drug. other million works interesting
seem to simple. However, side with effects Lurasidone of mechanism NRX-XXX. neutralized of have the to action The those addition we is
cell In have and cell amino mimics to the Animal acid into glycine gets the walls. DCS inhibits amino and don't however, the causes incorporated wall alanine cell, bacterium, NMDA bacteria In the a brain DCS cells a acid explode. mimics receptor. the
review partner to At of know that potent expect this agent published complicated resistant in of we invite the patent a DCS any engaged means for is a what It antibiotic antibiotics, understand cause already that bacteria literature opportunity. important to and data for harm that is why rate, only read So were marketing peer you in that has in product FDA X designation QIDP even millions UTI seen to NRX-XXX this identify week, It's means. effect we're the of drug entitled just that review. the we That's we of think against to as fast treatment now without application NRX-XXX track the use a in that The anti-infective this a and Americans, we in real bacteria. results. years space. in market priority exclusivity, a bugs we last for peer-reviewed designation identify
Steve's achievements address quarter follows. corporate some to during and now our the that going XXXX of
